Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease

Contributed by: Business Wire

Logo

Tags

Research

General Health

Professional Services

Genetics

Health Insurance

Public Relations/Investor Relations

Clinical Trials

Science

Biotechnology

Communications

Finance

Health

Other Science

Prasinezumab

More Like This

Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease

Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026

Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs

Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program

Prothena Reports Second Quarter 2025 Financial Results and Business Highlights

Lundbeck advances Parkinson's research with new Phase 1b data at AD/PD™ 2026

Prothena Reports Third Quarter 2024 Financial Results and Business Highlights

Prothena Announces Corporate Restructuring